NUREXONE BIOLOGIC INC

NurExone Biologic reports doubled exosome output with a modular, parallel reactor strategy, boosting yield without compromising quality – a key move for its spinal injury therapies.

NRX.V drops 1.82% on TSX Venture—find out why Nurexone Biologic’s stock slid below its 200‑day SMA, the latest clinical updates, and market context.